An interventional study of Dexmedetomidine and ketorolac in Tourniquet-induced Pain and Procedural Pain, sponsored by Mayo Hospital Lahore. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Mayo Hospital Lahore · Not applicable, Interventional, and Treatment
This study compared ketorolac and dexmedetomidine when added to lignocaine to prevent pain caused by a tourniquet during intravenous regional anesthesia. This technique involved injecting a local anesthetic into a vein to numb an arm or leg for surgery. A tourniquet, a tight cuff placed around the limb, restricted blood flow but could cause pain during the procedure.
The study was conducted at Mayo Hospital, Lahore, and was designed to include 70 patients aged 18-60 years undergoing surgery on the lower part of an arm or leg. Two treatment groups of 35 patients each received lignocaine with either dexmedetomidine or ketorolac. Pain was assessed on a scale from 0 to 10 at 15, 30, and 45 minutes after tourniquet application. Additional pain relief was administered when the pain score reached 4 or higher.
242 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.
This study's enrollment of 70 is below the median of 83 across 227 interventional studies indexed under Pain, Procedural.
Browse Pain, Procedural studies →Mayo Hospital Lahore is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients received dexmedetomidine 0.5 micrograms/kg with 0.5% lignocaine at 3 mg/kg for intravenous regional anesthesia.
Drug: Dexmedetomidine · Drug: Lidocaine
Patients received ketorolac 30 mg with 0.5% lignocaine at 3 mg/kg for intravenous regional anesthesia.
Drug: ketorolac · Drug: Lidocaine
Dexmedetomidine 0.5 micrograms/kg was administered as an adjunct to lignocaine for prevention of tourniquet-induced pain during intravenous regional anesthesia.
Ketorolac 30 mg was administered as an adjunct to lignocaine for prevention of tourniquet-induced pain during intravenous regional anesthesia.
Lidocaine 0.5% at 3 mg/kg was administered for intravenous regional anesthesia in both treatment groups.
Mean Time to First Rescue Analgesic Requirement
The mean interval, in minutes, from tourniquet application until the first requirement for rescue analgesia was compared between the treatment groups. Rescue analgesia was required when the Visual Analog Scale pain score reached 4 or higher and was administered as intravenous nalbuphine 0.07 mg/kg.
Time frame: From tourniquet application until the first rescue analgesic requirement or the end of surgery.
Tourniquet Pain Intensity
Tourniquet-related pain was assessed using the Visual Analog Scale. Mean pain scores were compared between the treatment groups, with higher scores representing greater pain intensity.
Time frame: At 15, 30, and 45 minutes after tourniquet application.
Time to Onset of Sensory Blockade
The interval, in minutes, from administration of the study drugs until sensory blockade was established was recorded. Sensory blockade was assessed using the pinprick sensation test.
Time frame: From administration of the study drugs until sensory blockade was established, before surgery.
Time to Onset of Motor Blockade
The interval, in minutes, from administration of the study drugs until motor blockade was established was recorded. Motor blockade was assessed by the absence of voluntary movements in the operative limb.
Time frame: From administration of the study drugs until motor blockade was established, before surgery.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Mayo Hospital Lahore